Full Dataset from Phase 2a trial in Parkinson’s Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated ...
Despite the short half-life of levodopa, in early PD, the symptomatic benefit of levodopa/DDCI appears to last from dose to dose when administered on a three- or four-times daily schedule.